Drug Industry Denied Fast Relief in Nevada Price Law Challenge

A new Nevada pricing transparency law for diabetes drugs remains alive, disappointing pharmaceutical industry groups that wanted the law to be rescinded immediately ( Pharm. Research & Mfrs. of Am. v. Sandoval, 2017 BL 325250, D. Nev., Case No. 2:17-CV-2315 JCM (CWH), 9/14/17).

Judge James C. Mahan of the U.S. District Court for the District of Nevada declined an invitation from the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) to kill the Nevada law outright. The court said the groups hadn’t shown they were entitled to immediate relief.

PhRMA and BIO are seeking ...